BNP (B-type Natriuretic Peptide) vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | Teriparatide |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 20 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 52–104 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
BNP (B-type Natriuretic Peptide), Teriparatide are both commonly used for:
Which Has Stronger Evidence?
- Recovery & Healing: Teriparatide has stronger research support.
| Goal | BNP (B-type Natriuretic Peptide) | Teriparatide |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
BNP (B-type Natriuretic Peptide)
- Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 2025
- Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP.
Circulation research, 2023
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.
Clinical chemistry, 2023
Teriparatide
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
JAMA, 2026
- The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis.
The Journal of clinical endocrinology and metabolism, 2025
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.
Journal of bone and mineral metabolism, 2025
Ready to Learn More?
Looking for trusted sources?